comparemela.com

Latest Breaking News On - Pharmabcine inc - Page 5 : comparemela.com

South Korea lays focus on novel mRNA therapeutics

NuclixBio announces a collaborative research agreement with ¸

South-korea
South-korean
Pharmabcine-inc
Nuclixbio-inc
Nuclixbio
Nuclixbio
Rna
Research
Partnership

NuclixBio Announces a Collaborative Research Agreement with PharmAbcine

SEOUL, South Korea, March 14, 2022 /PRNewswire/ NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA.

Seoul
Soult-ukpyolsi
South-korea
South-korean
Hoyoung-kang
Jin-san-yoo
Pharmabcine-inc
Youtube
Nuclixbio-inc
Prnewswire-nuclixbio-inc
Linkedin
Collaborative-research-agreement

PharmAbcine to Present Updated Data of Its Anti-VISTA Antibody Candidate at AACR 2022

/PRNewswire/ PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today.

Louisiana
United-states
Daejeon
Taejon-gwangyoksi
South-korea
New-orleans
American
Jin-san-yoo
Linkedin
Korean-society-of-medical-oncology
Business-development-team
Ir-pr-team

PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial

/PRNewswire/ PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics,.

Australia
Daejeon
Taejon-gwangyoksi
South-korea
United-states
San-antonio
Texas
Kenilworth
Queensland
Australian
Jin-san-yoo
Human-research-ethics-committee

PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial

DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the developm.

Australia
Daejeon
Taejon-gwangyoksi
South-korea
United-states
San-antonio
Texas
Kenilworth
Queensland
Australian
Jin-san-yoo
Human-research-ethics-committee

vimarsana © 2020. All Rights Reserved.